News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
April, 2025
April 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Tom Powles: 1st perioperative immune therapy study to show an OS in bladder cancer
Tom Powles/bartscancer.london
Sep 30, 2024, 16:54

Tom Powles: 1st perioperative immune therapy study to show an OS in bladder cancer

Tom Powles shared an article on X:

“Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer is the 1st perioperative immune therapy study to show an OS in bladder cancer.

Published in The New England Journal of Medicine.”

Tittle: Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer

Author: Thomas Powles, James W.F. Catto, Matthew D. Galsky, Hikmat Al-Ahmadie,Joshua J. Meeks, Hiroyuki Nishiyama and Toan Quang Vu.

Tom Powles: 1st perioperative immune therapy study to show an OS in bladder cancer

Source: Tom Powles/X

Professor Thomas Powles, specializing in urology cancer, holds the position of Professor at the University of London since 2012 and serves as the Director of Barts Cancer Centre, a CRUK Major Cancer Centre. With a role in biomarker development and drug strategies, he has secured multiple EMA and FDA approvals. His achievements include advancing front-line immune/targeted therapy combinations in RCC and immune checkpoint inhibition in bladder cancer.

bladder cancer chemotherapy Hiroyuki Nishiyama immune therapy James W.F. Catto Matthew D. Galsky Perioperative Durvalumab Thomas Powles Toan Quang Vu Tom Powles
Special Coverage
Blog
Apr 22, 2025, 19:24
Esra Bilir: Great pleasure and honor to interview Nadeem Abu-Rustum
Blog
Apr 22, 2025, 18:41
Nurses Community of Practice and GPON Spotlight Advocacy in Precision Oncology - FT3
Blog
Apr 22, 2025, 18:28
Vidith Phillips: AI x Oncology - Research Highlights Shaping Cancer Care in 2025
Blog
Apr 22, 2025, 18:02
Afreen Shariff: Fatigue is not just a side effect - it’s a serious complex, and often overlooked challenge in cancer care
Blog
Apr 22, 2025, 17:31
Vivek Subbiah: It's moments like these that remind me why I do what I do
Positive
Apr 22, 2025, 17:21
Foundation S marks 20 years of impact through My Child Matters - Childhood Cancer International
Blog
Apr 22, 2025, 17:11
Lisa A. Lacasse: We’re able to elevate the patient voice in the fight against cancer at every level of government
Blog
Apr 22, 2025, 17:05
Paul Ekert presents ZERO program at St. Jude Symposium - Children's Cancer Institute
Blog
Apr 22, 2025, 16:58
Wafik S. El-Deiry: Best Practices for Sponsored Research event
Opinion
Apr 22, 2025, 16:42
Nathan Pennell: The Medical community needs to oppose the Department of Justice's threats to journal independence
Blog
Apr 22, 2025, 16:28
Ruben Mesa: Celebrating the extraordinary 27 year tenure of Bayard Powell as the Chief of Hematology and Medical Oncology
Career
Apr 22, 2025, 16:21
Five MD Anderson researchers were honored with 2025 AACR Scientific Achievement Awards